Goldman Sachs Maintains Neutral on Sage Therapeutics, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter maintains a Neutral rating on Sage Therapeutics (NASDAQ:SAGE) but lowers the price target from $19 to $11.
July 26, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs has maintained a Neutral rating on Sage Therapeutics but has significantly lowered the price target from $19 to $11.
The significant reduction in the price target from $19 to $11 by a major financial institution like Goldman Sachs is likely to negatively impact investor sentiment and the short-term stock price of Sage Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100